Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$525.99 - $1,211.20
Previous CloseN/A
Volume208.99K
Average Volume (3M)1.04M
Market Cap
$65.24B
Enterprise Value$74.99B
Total Cash (Recent Filing)$117.31M
Total Debt (Recent Filing)$156.90M
Price to Earnings (P/E)15.6
Beta0.61
Next Earnings
Apr 29, 2025EPS Estimate
8.62Last Dividend Ex-Date
Feb 20, 2025Dividend Yield0.15%
Share Statistics
EPS (TTM)38.28
Shares Outstanding106,951,515
10 Day Avg. Volume1,045,282
30 Day Avg. Volume1,042,243
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)N/A
Price to Sales (P/S)5.07
Price to Cash Flow (P/CF)14.30
P/FCF Ratio14.10
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.13
Enterprise Value/Ebitda15.59
Forecast
1Y Price Target
$876.40Price Target Upside45.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
---
Bulls Say, Bears Say
Bulls Say
International Market ExpansionThere is strong growth potential in international markets for Vabysmo, where efforts to secure reimbursement and launch new products are ongoing.
Market Share GainsRoche expects Vabysmo to gain more share from competitors in the branded market, despite current challenges.
Pipeline And R&DRegeneron is considered a blue-chip biotech with a good R&D track record and various pipeline readouts that could be important if positive.
Bears Say
Competitive PressureExpect EYLEA headwinds to continue, given biosimilar launch and inventory.
Earnings And Revenue DeclineProduct sales and total revenues are expected to decrease significantly due to the impact of patient assistance funds closing.
Patient Assistance Funding IssuesPatient assistance funding challenges are expected to persist, impacting Eylea and leading to revised growth expectations for Regeneron.
---
Ownership Overview
1.94% Insiders
30.24% Mutual Funds
0.78% Other Institutional Investors
40.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $525.99 and its highest was $1211.20 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $65.24B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Apr 29, 2025 which is in 3 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Feb 04, 2025. The company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.282 by $0.788.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron pays a Notavailable dividend of $0.879 which represents an annual dividend yield of 0.15%. See more information on Regeneron dividends here
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 8.62.
How many shares outstanding does Regeneron have?
Regeneron has 106,951,515 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $12.07 in its last earnings report, beating expectations of $11.282. Following the earnings report the stock price went up 4.53%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in REGN
---
Regeneron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$876.40 (45.43% Upside)
$876.40 (45.43% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 28.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.75%
12-Months-Change
Fundamentals
Return on Equity
15.95%
Trailing 12-Months
Asset Growth
14.25%
Trailing 12-Months
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
---
REGN Company Deck
---
REGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Regeneron's strong financial performance, driven by key products and a robust pipeline. However, challenges such as competitive pressure on EYLEA and increased R&D expenses were noted. The company's strategic capital allocation and pipeline advancements position it well for future growth.Read More>---
REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
REGN Stock 12 Month Forecast
Average Price Target
$876.40
▲(45.43% Upside)
Technical Analysis
Best Analysts Covering REGN
1 Year
1 Year Success Rate
27/41 ratings generated profit
1 Year Average Return
+10.34%
assigned a buy rating 3 months ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 65.85% of your transactions generating a profit, with an average return of +10.34% per trade.
---